share_log

6-K: Gepotidacin Accepted for Priority Review by Us Fda for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

6-K: Gepotidacin Accepted for Priority Review by Us Fda for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

Gepotidacin用於治療女性成人和青少年單純性尿路感染獲得美國FDA優先審查
美股SEC公告 ·  10/16 06:27
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息